In 2012 T.A. Sciences® acquired the worldwide rights to a new patent-pending compound that has the potential to prevent or treat many diseases associated with aging
This exciting drug candidate has already undergone various enabling studies required by the U.S. Food and Drug Administration (FDA) to file an Investigational New Drug Application (INDA) for its use in patients with pulmonary fibrosis, a lung disease that can be fatal.
T.A. Sciences’® 2014 research plan includes funding to continue this promising project. It is the company’s intention to develop products that can address many other diseases in addition to pulmonary fibrosis. Ameliorating conditions associated with aging fits into the core expertise of T.A. Sciences®.
Therapeutic drugs utilizing the patented compound will require full FDA approval before they can be sold to the public. It will take many years and much more investment before T.A. Sciences® will possibly introduce an FDA-approved drug.
Please check back here for more updates on our progress in developing therapeutic drugs.